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 ABSTRACT 
Cadmium (Cd) is a carcinogenic heavy metal which is implicated in breast cancer 
by epidemiological studies. In cell culture studies, it is reported to promote breast 
cancer cell growth through membrane estrogen receptors. Triple-negative breast 
cancer patients are non-responsive to endocrine and trastuzumab therapy and have the 
worst prognosis and lowest survival rate. The purpose of this study was to examine 
whether Cd can promote the growth of non-metastatic, triple-negative human breast 
cancer cells HCC 1937, which are positive for epidermal growth factor receptor 
(EGFR). It was found that Cd treatment (0.1-0.5 μM) promoted cell growth and 
accelerated cell cycle progression by increasing cyclins A, B, and E, and CDK 1, and 
2 expressions. Further study using kinase inhibitors indicated that MAPK and PI3K 
activation was required for this process. The kinase activation in turn was mediated 
through EGFR activation. Based on these findings, it is concluded that sub-
micromolar concentration of Cd induces proliferation of HCC 1937 cells through 
EGFR, MAPK and PI3K regulated cell cycle progression. The involvement of EGFR 
in Cd-stimulated early stage and triple-negative breast cancer cell growth implicates 
Cd’s role in breast cancer progression. 
Keywords: Cadmium, Breast Cancer, Cell Proliferation, Cell Cycle, EGFR
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Cadmium promotes proliferation of triple-negative breast cancer cells through 
EGFR-mediated cell cycle regulation  
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BACKGROUND 
 
Cadmium exposure and health risk 
Cadmium (Cd) is a toxic element and an environmental contaminant with growing 
health concerns. Occupational exposure to Cd is mainly through inhalation. General 
population is predominantly exposed to Cd via dietary intake, smoking and polluted 
air. Bioaccumulation of Cd in the body interferes with normal physiological functions. 
Dietary Cd intake ranges from 0.5-55 μg/day (Cho et al., 2013). Absorbed Cd mainly 
binds to metallothionein or other cysteine-rich proteins in various organs, such as liver, 
kidney, lungs, prostate, spleen, mammary gland and heart (Cikrt et al., 1990; Cikrt et 
al., 1992).  
Acute exposure to Cd at high concentration induces cellular stress, impairs 
mitochondrial function, DNA damage and cell death (Petanidis et al., 2013). Chronic 
exposure to low concentration of Cd (dietary intake level) causes deregulated cell 
growth because of endocrine disruption. Epidemiology studies showed that dietary Cd 
intake is associated with breast cancer incidence (Julin et al., 2012; Itoh et al., 2014). 
In ovariectomized rat model, single ip injection of 5 µg/kg Cd promoted mammary 
gland and uterus growth, which indicated that Cd behaved like a metalloestrogen at 
low concentration (Johnson et al., 2003; Hofer et al., 2009). Several in vitro studies 
reported that Cd could stimulate MCF7 and T47D cell proliferation (Garcia-Morales et 
al., 1994; Martin et al., 2003; Zang et al., 2009). However, Silva et al. (2006) failed to 
detect Cd’s proliferative effect on the MCF7 cells. Still, Cd is accepted by many as an 
endocrine disruptor since some of its effects are similar to those of estrogen.  
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Cd as a xenoestrogen  
Most researchers attribute Cd’s estrogenic effect to the activation of estrogen 
receptor (ER). Garcia-Morales et al. (1994) first reported that low concentration of Cd 
stimulated MCF7 cell proliferation and induced transcription of ER regulated genes 
for cell growth. They concluded that Cd’s estrogenic effect was ER dependent based 
on two observations: 1) Cd’s estrogenicity was inhibited by ER inhibitor, ICI-164,384,  
2) MDA-MB-231, an ER negative cell line, did not respond to Cd’s estrogenic effect 
unless transfected with ER. To confirm that Cd interferes with the ER, Cd’s binding 
behavior to ER was studied by several groups. In ERα binding assay, radiolabeled 
109
Cd was shown to bind to ligand binding domain (LBD) of human recombinant ERα 
in a noncompetitive manner against estradiol (Stoica et al., 2000). Recently, RIfS 
(reflectometric interference spectroscopy), a label-free method, was utilized to study 
interaction between Cd and human ERα. It was reported that Cd was bound to cysteine 
residues in the LBD and changed ERα conformation without affecting estradiol 
binding to LBD of ERα (Fechner et al., 2011). 
Cd’s estrogenic effect is implemented by direct affecting ERα, and modulating 
ERα responsive signaling pathways. At the receptor level, Cd phosphorylates ERα and 
increases ERα translocation. Furthermore, it potentiates the interaction of ERα and c-
jun which binds to other promoter regions and regulates c-myc and cyclin D1 leading 
to cell proliferation (Siewit et al., 2010; Ponce et al., 2013). At signaling level, Cd 
activates ERα-mediated pathways. It activates MAPK pathway and pERK reaches the 
nucleus, which recruits proto-oncongenes c-fos and c-jun to form transcription factors 
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AP-1, thereby increasing transcription of cell growth responsive genes. Constitutive 
transcription of these genes contributes to breast cancer progression (Choe et al., 2003; 
Liu et al., 2008; Zang et al., 2009). 
 
Activation of mitogenic pathway and cell cycle progression 
Cell cycle is a process of cell division in which a parent cell divides into two 
daughter cells. Quiescent (non-dividing) cells are considered in G0 phase. When cell 
enters into the G1 phase, cell size increases and the cell prepares for DNA synthesis. 
Cells that enter the G1 phase but not pass restriction point go back to G0 phase. Cells 
that pass the restriction point move forward through G1/S/G2/M phases sequentially 
(Lim and Kaldis, 2013). G1/S and G2/M transitions are crucial checkpoints for cell 
cycle progression. The transition of cells from one phase to the next requires cyclins 
and CDKs working properly. Cell cycle regulation is a complicated system which is 
regulated by various kinase pathways. Mitogenic signaling control of cell cycle 
transition is well documented (Massague, 2004). When mitogen activates MAPK and 
PI3K, their downstream signals translocate and activate transcription factors such as 
myc and AP-1 which are responsible for enhancing cyclin/CDK complex formation 
(Shaulian and Karin, 2001). At G1/S transition, cyclin D/CDK 4, cyclin E/CDK 2 
complexes phosphorylate retinoblastoma protein (Rb). Thereby E2F is released from 
Rb. Released E2F further promotes expression of cyclin A and CDK 2 which promote 
cells to enter S phase. At the end of S phase, accumulated cyclin A/CDK 2 complexes 
phosphorylate FoxM1, leading to the relief of its self-inhibition. Then FoxM1 recruits 
histone deacetylase p300/CREB binding protein (CBP) and transcribe cyclin B and 
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centromere protein F which are executor for entering mitosis (M phase) (Major et al., 
2004; Laoukili et al., 2008; Park et al., 2008; Chen et al., 2009). 
 
Role of EGFR in breast cancer development 
Breast cancer has five subclasses based on presence of ERα/β, progesterone 
receptor (PR) and human epidermal growth factor 2 (HER2). Triple-negative cancer 
cells are negative for all of these. Approximately 20% of breast cancer patients are 
defined as triple-negative They have worse prognosis and survival rate because the 
breast cancer cells are highly malignant, more aggressive and unresponsive to 
endocrine treatment and trastuzumab (Herold and Anders, 2013). However, triple-
negative breast cancer patients treated with dual EGFR and HER2 inhibitors have 
better overall survival rate (Chen and Russo, 2011). Therefore, EGFR is an important 
biomarker for breast cancer treatment and prognosis. The clinical therapy in triple-
negative breast cancer patient prompts EGFR as the target to study the tumorigenesis 
potential of Cd in the absence of ER.  
It is established that EGFR is the crucial receptor associated with cell proliferation 
and cell cycle progression. EGFR is a 170 kDa transmembrane glycoprotein expressed 
on many epithelial cells. It has an extracellular receptor binding domain and a 
cytoplasmic tyrosine kinase domain. When ligands bind to EGFR, the receptor 
dimerizes and results in EGFR and downstream kinase phosphorylation. The pEGFR 
translocates and phosphorylates transcriptional factors such as E2F1 and STAT3 
which facilitate cell cycle progression and proliferation (Lo et al., 2005; Lo et al., 
2006; Hanada et al., 2006;). The activated downstream pathways include MAPK, 
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PI3K and PLC. MAPK pathway promotes cell growth and PI3K/AKT pathway 
prevents apoptosis. Both downstream pathways lead to enhanced activity of 
transcription factors such as NFкB and c-myc which result in increasing DNA 
synthesis, cyclins and CDKs expression, and cell proliferation (Hoadley et al., 2007; 
Kundu et al., 2013). It is reported that Cd induces A549 human lung adenocarcinoma 
cell proliferation through EGFR (Kundu et al., 2011). So EGFR may be responsible 
for Cd’s effect on cell proliferation and cell cycle progression. 
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ABSTRACT 
Cadmium (Cd) is a carcinogenic heavy metal which is implicated in breast cancer 
by epidemiological studies. In cell culture studies, it is reported to promote breast 
cancer cell growth through membrane estrogen receptors. Triple-negative breast 
cancer patients are non-responsive to endocrine and trastuzumab therapy and have the 
worst prognosis and lowest survival rate. The purpose of this study was to examine 
whether Cd can promote the growth of non-metastatic, triple-negative human breast 
cancer cells HCC 1937, which are positive for epidermal growth factor receptor 
(EGFR). It was found that Cd treatment (0.1-0.5 μM) promoted cell growth and 
accelerated cell cycle progression by increasing cyclins A, B, and E, and CDK 1, and 
2 expressions. Further study using kinase inhibitors indicated that MAPK and PI3K 
activation was required for this process. The kinase activation in turn was mediated 
through EGFR activation. Based on these findings, it is concluded that sub-
micromolar concentration of Cd induce proliferation of HCC 1937 cells through 
EGFR, MAPK and PI3K regulated cell cycle progression. The involvement of EGFR 
in Cd-stimulated early stage and triple-negative breast cancer cell growth implicates 
Cd’s role in breast cancer progression. 
Keywords: Cadmium, Breast Cancer, Cell Proliferation, Cell Cycle, EGFR 
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INTRODUCTION 
 
Cadmium (Cd) is a toxic metal which is widely distributed in the environment. It 
is used in pigment, metal-plating, battery and plastics industries. The general 
population is exposed to Cd from fuel combustion, waste burning, and cigarette 
smoking, and through dietary intake from food and polluted water (Huang et al., 2013). 
Besides the acute toxicity to kidney and bone, Cd is an established Group 1 carcinogen 
because of its causative effect on lung cancer (Stayner et al., 1992). Retrospective and 
prospective epidemiology studies indicate that dietary Cd intake is associated with 
breast cancer incidence (Julin et al., 2012; Itoh et al., 2014). Also, bioaccumulation of 
Cd in breast tissue of breast cancer patients is higher than of normal subjects 
(Romanowicz-Makowska et al., 2011; Strumylaite et al., 2011). In studies with rats, 
Cd was found to be a highly potent endocrine disruptor because it promoted growth of 
mammary gland and uterus by a single i.p. injection of 5 µg/kg Cd (Johnson et al., 
2003; Hofer et al., 2009). 
The mechanism of breast cancer cell growth promotion by Cd has been explored 
by a number of investigators. Garcia-Morales et al. (1994) found that Cd stimulated 
the growth of MCF-7 cells by activating estrogen receptor alpha (ERα) and inducing 
the expression of ERα targeted genes which were involved in cell growth. Cd has also 
been shown to bind to the ligand-binding domain of ERα in a noncompetitive manner 
against estradiol (Stoica et al., 2000). Several other studies have confirmed that Cd 
stimulates the proliferation of ER-positive MCF7 and T47D cells (Martin et al., 2003; 
Zang et al., 2009). However, Silva et al. (2006) were unable to observe the 
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estrogenicity of Cd in MCF7 cells by E-Screen assay. Yu et al. (2010) reported that Cd 
stimulated cell growth via G protein coupled receptor 30 (GPR30) in ERα negative 
breast cancer cell line SKBR3. Furthermore, in a transgenic estrogen response element 
(ERE)-luciferase reporter mouse model, Cd did not increase the ERE-luciferase 
activities in any reproductive or non-reproductive organ (Ali et al., 2010; Ali et al., 
2012). Still, most researchers accept Cd as an endocrine disruptor since a number of 
its effects are similar to those of estrogen. 
Although currently there is no consensus on whether Cd’s estrogenic effect is ER 
mediated, there is a general agreement that Cd activates the mitogen signaling 
pathways such as mitogen-activated protein kinase (MAPK) and phosphoinositide 3-
kinase (PI3K) in breast cancer cells (Choe et al., 2003; Liu et al., 2008; Zang et al., 
2009). These pathways converge signaling from various membrane receptors, 
including ERs, G-protein coupled receptors (GPCRs), and receptor tyrosine kinases 
(RTKs), and cause the activation of genes involved in cell cycle regulation, 
proliferation, and survival (Martin et al., 2000). Epidermal growth factor receptor 
(EGFR) is one of the RTKs which plays a pivotal role in integrating hormone-
mediated growth factor stimulation and subsequent activation of MAPK and PI3K 
pathways (Yarden and Sliwkowski, 2001; Filardo et al., 2002; Navolanic et al., 2003).  
We hypothesized that, in addition to ERs, EGFR might be involved in promoting 
the proliferation of breast cancer cells. To test this hypothesis, we utilized an early 
stage human ductal breast cancer cell line, HCC 1937. These cells are triple-negative 
with respect to ER, progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2), but are positive for EGFR. This early stage triple-negative breast 
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cancer cell line renders a good model to study the tumorigenic potential of Cd in the 
absence of ER. Based on a series of experiments with the HCC 1937 cells, we present 
here four observations regarding Cd-induced human breast cancer cell proliferation:  
1) ER is not essential for Cd’s action.  
2) The cell cycle signal is initiated at the cell membrane through EGFR. 
3) Intracellular signal transduction involves activation of MAPK and PI3K. 
4) In the nucleus, cyclins and CDKs facilitate cell cycle progression. 
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MATERIALS AND METHODS 
 
Materials  RPMI 1640 and Trypsin-Versene were purchased from Lonza 
(Walkersville, MD). Fetal bovine serum was purchased from Atlanta Biologicals 
(Flowery Branch, GA). Phenol red-free RPMI 1640 medium was purchased from Life 
Technologies (Grand Island, NY). MTT, BSA, DMSO, PMSF and protease inhibitor 
were purchased from Sigma-Aldrich (Dallas, TX). Acrylamide-Bis acrylamide powder 
and BCA kit were purchased from Fisher Scientiﬁc (Pittsburgh, PA). Phosphatase 
inhibitor cocktail tablet was purchased from Roche (Indianapolis, IN). Laemmli buffer 
and blotting buffers were obtained from Bio-Rad (Hercules, CA). PD 184161, 
wortmannin and AG 1478 were purchased from Cayman Chemical (Ann Arbor, 
Michigan). Propidium iodide staining solution was part of Apoptosis Detection Kit 
from BD Bioscience (San Jose, CA). Phospho-p44/42, p44/42, phosphor-AKT and 
AKT primary antibodies were from Cell Signaling Technology (Danvers, MA). Cyclin 
A (H-432), cyclin B1 (M-20), cyclin E (M-20), CDK 1 (p34) and CDK 2 (H-298) 
were obtained from Santa Cruz Biotechnology (Dallas, TX). EGFR siRNA and 
transfection reagent were obtained from Thermo Scientific (Pittsburgh PA). 
Cell Culture  HCC 1937 cells were obtain from ATCC and cultured in RPMI 
1640 medium in the presence of 5% CO2 at 37℃. The medium was supplemented with 
10% FBS, 100 unit/ml penicillin, 100 μg/ml streptomycin and non-essential amino 
acids. 
Cell proliferation assay  The cells were seeded into 24-well plates at a density of 
8×103 cells/well in phenol red-free RPMI 1640 medium. After 24 h, the cells were 
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serum-starved and cultured in 0.2% BSA-supplemented phenol red-free RPMI 1640 
medium for 48 h. Following this, the cells were treated with 0.05, 0.1 or 0.5 μΜ CdCl2 
in phenol-red free RPMI 1640 for 4 days. The medium was changed every 2 days. At 
the end of Cd treatment, the cells were incubated with 10% MTT solution (5 mg/ml) 
for 3 h. The MTT solution was aspirated and formazan was dissolved by DMSO. Cell 
viability was determined by measuring absorbance at 570 nm minus the background 
absorbance at 690 nm.  
Flow cytometry  HCC 1937 cells were seeded in 6-well plates at a density of 4×
10
4 
cells/well and serum-starved as described above. The cells were treated with 0.05, 
0.1, 0.5 or 1 μM CdCl2 in phenol red-free RPMI 1640. At the end of Cd treatment, 
cells were harvested and fixed overnight in 70% ethanol. For measuring DNA content 
by flow cytometry, the cells were washed with PBS before staining with a solution of 
18 μg/mL propidium iodide and 40 μg/mL RNase A for 40 min. 
siRNA transfection  HCC 1937 cells were seeded in 12-well plates at a density of 
2×104 cells/well in RPMI 1640 medium containing 10% FBS. Cell culture medium 
was replaced by fresh complete medium before siRNA transfection. Each well was 
transfected with 2 μl EGFR siRNA (20 μM) and 2 μl transfection reagent for 48 h. The 
cells were serum-starved in 0.2% BSA-supplemented phenol red-free RPMI 1640 
medium for 12 h before treatment with Cd.  
Immunoblotting  HCC 1937 cells were seeded in 6-well plates and serum-starved 
as described above. To detect cyclin and CDK expression, the cells were treated with 
CdCl2 for 48 h in 0.2 % BSA-supplemented phenol red-free RPMI 1640 medium. To 
observe ERK and AKT phosphorylation, the cells were treated with CdCl2 for up to 6 
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h in serum-free RPMI 1640 medium. The cells were washed with PBS before harvest 
and lysed in RIPA Buffer supplemented with protease inhibitor (1:1000 dilution), 2 
mM PMSF and phosphatase inhibitor (10 ml/tablet). The lysate was centrifuged at 
12,000 rpm for 10 min at 4℃. The supernatant was heated to 95℃ with laemmli buffer 
containing 5% β-mercaptoethanol. Protein concentration was measured by BCA kit 
and the same amount of protein was applied to each well before electrophoresis. SD 
Semi-dry Transfer Cell was used to transfer protein to nitrocellulose membrane at 24V 
for 1 h. The membrane was blocked in 5% non-fat milk for 1 h and incubated with 
corresponding primary antibody at 4℃ overnight. The membrane was washed 3×10 
min with 0.1% PBST before incubation with the secondary antibody at 1:10000 
dilution. The protein bands on the membrane were scanned by using  Odyssey Infrared 
Imager after PBST washing for 3×10 min. 
Data analysis  All experiments were repeated at least three times. Flow cytometry 
data were analyzed by ModFit LT Software. Western blot data were analyzed and 
quantified by Odyssey Infrared Imaging Software. One-way ANOVA was performed 
by SPSS followed by Tukey’s post hoc test at p<0.05.  
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RESULTS 
 
Effect of Cd on cell growth 
In order to establish that Cd promoted early stage cancer cell growth, HCC 1937 
cells, a triple-negative human breast cancer cell line, was used in this study. The cells 
were serum-starved prior to treatment with Cd and proliferation was measured by the 
MTT assay. As shown in Fig. 1, there was a markedly increased the cell density of 
HCC 1937 cells after four days of culture in the presence of Cd. The MTT assay 
revealed 23 and 45% increase in cell density at 0.1 and 0.5 μM Cd, respectively, when 
compared to the BSA control group.  
 
Effect of Cd on cell cycle progression 
To test whether Cd induced HCC 1937 cell growth by cell cycle progression, the 
cells were synchronized by 48 h serum starvation and treated with various 
concentrations of Cd for 24 h. Cells grown in the presence of 10% FBS were used as 
positive control. The distribution of different cell cycle phases was determined by 
using flow cytometry. The results were shown in Fig. 2, treatment with 0.05-0.5 μM 
Cd significantly increased the proportion of cell population in the G2/M phase. At the 
treatment with 0.5 μM Cd, there was a 57% increase over the BSA control group. 
Higher concentration of Cd (1 μM) was toxic in these cells. 
To determine the time-course of cell cycle progression, serum-starved cells were 
treated with 0.5 μM CdCl2 for 12-48 h. Cells grown in the presence of 10% FBS were 
used as positive control. As shown in Fig. 3, between 24 to 48 h treatment with 0.5 
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μM Cd, there was a 49-58% increase in proportion of cell population in the G2/M 
phase when compared to the BSA control. The increase of cell population in G2/M 
phase indicated Cd accelerated cell cycle progression. 
 
Effect of Cd on cyclins and CDKs 
Cell cycle progression is precisely regulated by periodic expression of phase-
specific heterodimeric protein kinases-cyclins (regulatory subunit) and cyclin-
dependent kinases (CDKs) (catalytic subunit). Cyclin D/CDK4 and 6 prompt cells 
entering cell cycle and drive the cells going through the G1 phase. Cyclin E/CDK 2 
complex is responsible for the G1/S transition. Cyclin A/CDK 2 and Cyclin B/CDK 1 
drive cell through the S and G2 phases, respectively. The effect of Cd on cyclins and 
CDKs expression was determined in serum-starved cells treated with 0.05-1 μM Cd 
for 48 h. The results were shown in Fig. 4, Cd treatment significantly increased cyclins 
A, B, and E, and CDK 1 and 2, however, not in a concentration-dependent manner, 
except cyclin E. It had no effect on the cyclin D level. The cyclin and CDK data 
indicated that Cd accelerated the progression of HCC 1937 cells into the G2/M phase.   
 
Effect of Cd on MAPK and PI3K activation  
MAPK and PI3K signaling pathways regulate cell growth and cell cycle 
progression. To test whether Cd activated these kinases, the time course and 
concentration response of ERK 1/2 and AKT phosphorylation were determined by 
western blot analysis. As shown in Fig. 5A, maximal ERK 1/2 phosphorylation by 0.5 
μM Cd was observed at 15 min, followed by a gradual decrease over the 2 h period. In 
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comparison, AKT phosphorylation peaked at 6 h after Cd treatment. As shown in Fig. 
5B, treatment with 0.1-1 μM Cd resulted in up to 2.5-fold increase in ERK 1/2 
phosphorylation at 15 min and up to 3-fold increase in AKT phosphorylation in 6 h.  
 
Role of ERK and AKT in the expression of cyclins and CDKs 
It is well known that MAPK and PI3K activations regulate cell cycle progression. 
To ascertain that Cd-induced cell cycle progression was also dependent on ERK and 
AKT phosphorylation, inhibitors of MEK (PD184161) and PI3K (Wortmannin) were 
utilized to check the effect on expression of cyclins and CDKs after Cd treatment. 
EGF was used as a positive control. As shown in Fig. 6, the inhibitors abrogated both 
Cd and EGF’s effects on cyclin and CDK expressions. These results confirmed that 
the activation of MAPK and PI3K pathways was required for Cd-induced increases in 
cyclins and CDKs.  
 
 
Role of EGFR on Cd-induced MAPK and PI3K activation 
EGFR is a key receptor that mediates MAPK and PI3K pathways. In ER negative 
cells, Cd-induced kinase activation may be mediated through other membrane 
receptors such as EGFR. To identify the contribution of EGFR in Cd-induced cell 
cycle progression, an EGFR inhibitor (AG 1478) was utilized. The serum-starved cells 
were treated with 0.5 μM Cd or 10 ng/ml EGF in the presence or absence of 2 μM AG 
1478 for 15 min or 6 h. Both Cd- and EGF-induced ERK and AKT phosphorylation 
were completely eliminated by AG 1478 (Fig. 7).  
 20 
 
To further identify EGFR’s role in Cd-induced ERK phosphorylation, EGFR in 
HCC 1937 cells was knocked down by siRNA transfection. The transfected cells were 
serum-starved for 12 h and then treated with 0.5 μM Cd or 1 ng/ml EGF. Mock 
transfected cells were used as control. As shown in Fig. 8, EGFR siRNA and AG 1478 
both eliminated Cd-induced ERK phosphorylation. The blockage of EGFR-mediated 
MAKP and PI3K signaling will affect cell cycle progression. As shown in Fig. 9, the 
EGFR inhibitor decreased the Cd- and EGF-induced expressions of cyclins and CDKs. 
This indicated that EGFR was essential for Cd-induced cell cycle progression. 
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DISCUSSION 
 
At high concentration, Cd is toxic and causes cell cycle arrest (Yang et al., 2004; 
Xie and Shaikh, 2006). More recent studies have reported that at micromolar 
concentration Cd increases cell cycle progression in prostate epithelial cell, mesangial 
cells, and lung epithelial cells (Bakshi et al., 2008; Xiao et al., 2009; Kundu et al., 
2011; Kundu et al., 2013). The results reported in this study in breast cancer cells are 
similar to those reported in other types of cells.   
The present study showed that Cd prompted cells to enter G2/M phase without 
affecting G0/G1 phase, which is similar to what was observed in the presence of FBS. 
The mechanism of Cd-induced cell cycle progression appears to be through regulation 
of cyclins A, B, and E and CDK 1 and 2. Cyclin E/CDK 2 complex is responsible for 
G1/S transition and Cyclin A/CDK 2 and Cyclin B/CDK 1 drive cells through S phase 
and G2 phase, respectively (Lim and Kaldis, 2013). Therefore, increased expression of 
cyclins and CDKs accelerated cell progressing to G2/M phase. In the present study, 
Cd did not increase cyclin D expression, which supports the cell cycle results. No 
significant change in the proportion of cell population in G0/G1 phase was detected 
because HCC 1937 cells were transformed cells which had deregulated control of 
entering cell cycle (Klein and Assoian, 2008). So extracellular stimuli neither 
significantly affected the cells progression into G1 phase, nor increased the 
corresponding cyclin D expression.  
The cell cycle results indicated that Cd prompted cells to enter G2/M phase by 
activating mitogenic signals. Inhibition of MAPK and PI3K by PD 184161 and 
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Wortmannin resulted in suppressing the expression of cyclins and CDKs. Extensive 
studies report that progression into G2/M phase requires precise control of cell cycle 
machinery, which is regulated by kinases involved signal transduction through a series 
of steps. Activation of MAPK pathway leads to enhanced activity of transcription 
factors such as Myc, AP-1, E2F1 and STAT3 (Lo et al., 2005; Hanada et al., 2006; Lo 
et al., 2006). These transcription factors promote expression of cyclins and CDKs 
(Biswas et al., 2000; Major et al., 2004; Shelton et al., 2004; Laoukili et al., 2008; 
Park et al., 2008; Chen et al., 2009). Cyclin A/CDK 2 and Cyclin B/CDK 1 complexes 
sequentially phosphorylate FoxM1 to translocate into the nucleus and to transcribe 
executor of mitosis, such as cyclin B, and centromere protein F (Major et al., 2004; 
Laoukili et al., 2008; Park et al., 2008; Chen et al., 2009). Meanwhile, activation of the 
PI3K/AKT pathway induces the cell to progress to late G2 phase, but the mechanism 
is not fully understood (Liang and Slingerland, 2003; Ornelas et al., 2013). Although 
these details of mitogen-activated pathways were not investigated in the present study, 
the major cell cycle regulatory pathways are known to be well conserved (Shelton et 
al., 2004; Ma et al., 2010). 
Beside MAPK activation which has been described above, the activation of PI3K 
is commonly regarded as an anti-apoptotic signal because AKT phosphorylation 
induces anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) and survivin expression 
(Siddiqa et al., 2008). The sustained AKT activation contributes to pro-survival by 
directly inactivating caspase family (Longo et al., 2008). In this study, the relative 
long duration of AKT phosphorylation by Cd treatment explained Cd’s pro-
proliferative effect in HCC 1937 cells, which supported pro-survival effect of Cd in 
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MCF7 (Brama et al., 2007). Also, similar phosphorylation pattern of AKT was 
observed in cobalt promoted cell cycle progression (Ryu et al., 2010).  
Cd-induced MAPK and PI3K activation was previously studied in ER-positive cell 
lines such as MCF7 and T47D, which was attributed to Cd’s estrogenic effect on ER 
(Brama et al., 2007; Ponce et al., 2013). In ER-negative cells, Yu et al. (2010) reported 
that GPR30 mediated Cd’s estrogenic signaling. GPR30 functions by activating EGFR 
which causes rapid signaling of downstream cascade such as MAPK and PI3K 
(Filardo et al., 2002; Navolanic et al., 2003). The present study showed that Cd’s 
mitogenic effect in the triple-negative breast cancer cells required EGFR-mediated 
MAPK and PI3K activation and subsequent expression of cyclins and CDKs. 
In clinical therapy, EGFR is an important biomarker for triple negative breast 
cancer patients who are only responsive to EGFR/HER2 inhibitors (Chen and Russo, 
2011). It is reported that early stage ductal carcinoma with triple-negative receptor 
phenotype tends to proceed to invasive breast cancer (Bryan et al., 2006). Therefore, 
HCC1937 cell model renders a rational approach to study association between triple- 
MAPK and PI3K signaling pathways negative breast cancer and Cd exposure. Recent 
reports in lung epithelial cells and rat mesangial cells supported that Cd-induced cell 
proliferation was mediated via EGFR. The studies on lung epithelial cells showed that 
Cd activated EGFR and promoted an initial inflammatory response. With activated 
EGFR, NFκB upregulated the expression of pAKT, pSTAT3 and cyclin D1 which 
contributed to cell proliferation and cell cycle progression (Kundu et al., 2011; Kundu 
et al., 2013). The study on rat mesangial cells showed that Cd influences 
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Ca
2+
/calmodulin-dependent kinases which resulted in activation of EGFR and 
downstream Src, ERK and AKT phosphorylation (Xiao et al., 2009). 
EGFR and β1 integrin are reported to physically interact and are co-regulated and 
share most signaling pathways, such as PI3K/AKT and MAPK/ERK, Rho/Rac 
GTPase (Jeanes et al., 2012). It has been reported that Cd has high binding affinity 
with cysteine containing motifs in EGFR and integrin (Ahmadibeni et al., 2007). It is 
possible that Cd may cause cell proliferation through promoting the interaction 
between EGFR and integrin.  
In conclusion, the present study showed that submicromolar concentrations of Cd 
cause breast cancer cell proliferation by regulating cell cycle progression. By using 
kinase inhibitors, it was observed that Cd induces the expression of cyclins and CDKs 
by activation of MAPK and PI3K pathways. Furthermore, these mitogenic effects of 
Cd were mediated through its upstream effect on EGFR. 
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FIGURES 
 
 
 
  
 
 
 
Fig. 1. Effect of Cd treatment on growth of HCC 1937 cells. The cells were seeded 
in RPMI 1640 containing 10% FBS medium and starved in 0.2% BSA for 48 h. Then 
the cells were treated with Cd for 4 days. Cell growth was measured by the MTT assay. 
Data from three independent experiments were plotted as mean ± SE. The image 
under the graph shows one well of MTT stained cells/treatment. *Significantly 
different from the BSA control group (p<0.05, n=3). 
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Fig. 2.  Effect of Cd treatment on cell cycle progression. HCC 1937 cells were 
seeded in 10% FBS for 24 h and serum-starved for 48 h. Then cells were treated with 
0.05, 0.1, 0.5 or 1 μM CdCl2 for 24 h. Cells were harvested and fixed at the end of 
treatment. DNA was stained with PI. Proportion of cells in various phases of cell cycle 
was plotted as PI staining (y axis) versus DNA content (x axis). The mean ± SE of cell 
phase fraction in G0/G1, S and G2/M phase was plotted as bar graph. *Significantly 
different from the BSA control group (p<0.05, n=3). 
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Fig. 3. Time-course of cell cycle progression in response to Cd treatment. HCC 
1937 cells were seeded in RPMI 1640 containing 10% FBS for 24 h and serum-
starved for 48 h. Cells were treated with 0.5 μM CdCl2 for 12, 24, 36 or 48 h. BSA 
and FBS were negative and positive controls, respectively. Cells were harvested and 
fixed at the end of treatment. DNA was stained with PI. (A) Proportion of cells in 
various phases of cell cycle was plotted as PI staining (y axis) versus DNA content (x 
axis). (B) The mean ± SE of cell phase fraction in G0/G1, S and G2/M phase was 
plotted as line graph. *Significantly different from the BSA control group (p<0.05, 
n=6). 
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Fig. 4. Cyclin and CDK expression in response to Cd treatment. HCC 1937 cells 
were seeded in RPMI 1640 containing 10% FBS for 24 h and serum-starved for 48 h. 
Cells were treated with 0.05, 0.1, 0.5 or 1 μM CdCl2 for 48 h. Cell lysates were 
analyzed for cyclins A, B, D,and E, and CDK 1 and 2. Band intensity relative to the 
BSA control was plotted as bar graph showing mean ± SE. *Significantly different 
from the BSA control group (p<0.05, n=3). 
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Fig. 5. Time-course and concentration-response patterns of Cd-induced ERK and 
AKT phosphorylation. (A) Time-course. HCC 1937 cells were seeded in RPMI 1640 
containing 10% FBS for 24 h and serum-starved for 48 h. Cells were treated with 0.5 
μM CdCl2 for 0.25, 0.5, 0.75, 1 or 2 h. Cell lysates were analyzed for pERK 1/2. Cell 
lysates for cells treated with 0.5 μM CdCl2 for 1, 2, 4, 6 or 8 h were analyzed for 
pAKT. (B) Concentration-response. HCC 1937 cells were seeded in RPMI 1640 
containing 10% FBS for 24 h and serum-starved for 48 h. Cells were treated with 0.05, 
0.1, 0.5 or 1 μM CdCl2. Cells were harvested after 15 min to analyze pERK 1/2 and at 
6 h to analyze pAKT. Band intensity relative to the control was plotted as mean ± SE. 
*Significantly different from the control group (p<0.05, n=3). 
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Fig. 6. Effect of ERK and AKT inhibitors on expression of cyclin and CDK. HCC 
1937 cells were seeded in RPMI 1640 containing 10% FBS for 24 h and serum-
starved for 48 h. Cells were treated with 0.5 μM CdCl2 in the presence or absence of 
1μM PD 184161 and 1μM Wortmannin for 48 h. Cell lysates were analyzed for 
cyclins A, B , E and CDK 1, 2. Band intensity relative to the BSA control was plotted 
as bar graph showing mean ± SE. *Significantly different from the BSA control group 
(p<0.05, n=3). 
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Fig. 7. Effect of EGFR inhibitor on ERK and AKT phosphorylation. HCC 1937 
cells were seeded in RPMI 1640 containing 10% FBS for 24 h and serum-starved for 
48 h. Cells were treated with 0.5 μM CdCl2  in the presence or absence of 2 μM AG 
1478 for 15 min for analyzing pERK 1/2 and for 6 h for analyzing pAKT. Band 
intensity relative to the control was plotted as bar graph with mean ± 
SE.*Significantly different from the control group (p<0.05, n=3). 
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Fig. 8. Effect of EGFR inhibitor and siRNA on ERK phosphorylation. HCC 1937 
cells were seeded in RPMI 1640 containing 10% FBS for 24 h and transfected with 
EGFR siRNA for 48 h. Cells were serum starved in 0.2% BSA for 12 h before treating 
with 0.5, 1μM CdCl2 or 1 ng/ml EGF in the presence or absence of 2 μM AG 1478. 
Cells were harvested after 15 min treatment for analyzing pERK 1/2. Band intensity 
relative to the control was plotted as bar graph with mean ± SE.*Significantly 
different from the control group (p<0.05, n=3). 
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Fig. 9. Effect EGFR inhibitor on the expression of cyclins and CDKs. HCC 1937 
cells were seeded in 10% FBS for 24 h and serum-starved for 48 h. Cells were treated 
with 0.5 μM CdCl2 with or without 2 μM AG 1478 for 48 h and analyzed for cyclins A, 
B, and E, and CDK 1 and 2,. Band intensity relative to the control was plotted as bar 
graph with mean ± SE.*Significantly different from the control group (p<0.05, n=3). 
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